Saygin 2002.

Methods	DESIGN Description: random‐assignment, placebo‐controlled, parallel arm, flexible‐dose, single centre BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 60 DSM‐IV PTSD, earthquake survivors, mean age: 41.5 years, 76% (41/54) male, 9% (5/54) MDD, baseline severity on TOP‐8: nefazadone (15.75) and sertraline (19.27) SCREENING Primary diagnosis: SCID‐1 Comorbidity: Not mentioned
Interventions	Description: nefazadone 200 mg/d ‐ 400 mg/d (avg: 332.4 mg/d) versus sertraline 50 mg/d‐100 mg/d (avg: 68.3 mg/d) x 6 months
Outcomes	PDS, TOP‐8, CGI (no distinction between primary and secondary outcomes) Data estimation: Completer values
Notes	INDUSTRY SUPPORT Industry funded: No Medication provided by industry: No Any of the authors work for industry: No ADDITIONAL INFORMATION Drop‐out rates: 20% (6/30) on nefazadone and 0% on sertraline Quality rating score: 25 Not clear whether study was blinded
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear